- Prescribing Advice for GPs - https://www.prescriber.org.uk -

NICE Guidance - July 2021

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of July 2021. This month are two guidelines, four technology appraisals and one COVID-19 rapid guideline that impact upon primary care.

The Type 1 diabetes in adults: diagnosis and management guideline has been updated. It covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications. This updated amended the recommendations on long-acting insulin therapy.

The Clostridioides difficile infection: antimicrobial prescribing guideline has been published. It sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance.

The Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation technology appraisal has been updated. This update amended recommendation 1.2 to include consideration of the risks and benefits of this and other anticoagulants approved by NICE.

The Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation technology appraisal has been updated. This update amended recommendation 1.2 to include consideration of the risks and benefits of this and other anticoagulants approved by NICE.

The Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation technology appraisal has been updated. This update amended recommendation 1.2 to include consideration of the risks and benefits of this and other anticoagulants approved by NICE.

The Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation technology appraisal has been updated. This update amended recommendation 1.2 to include consideration of the risks and benefits of this and other anticoagulants approved by NICE.

The COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) guideline has been published. It covers vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome which has been reported in rare cases after COVID-19 vaccination. There is limited evidence available to inform clinical management, identification and management of the condition is evolving quickly as the case definition becomes clearer. This guideline was produced to support clinicians to diagnose and manage this newly recognised syndrome.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.